Clinical trials: Medically Intractable Epilepsy
Epilepsy
Controlled Randomized Vagus Nerve Stimulation (VNS) Therapy Versus Resection (CoRaVNStiR)
Background: There are a variety of treatment options for medically refractory medial temporal lobe epilepsy. Evidence from randomized trials indicates vagus nerve stimulation therapy can be used as a proven therapy for medically…
- Trial name
- CoRaVNStiR (NCT02089243)
- Testing
- Vagus nerve stimulation therapy, Resective surgery
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xijing Hospital
Epilepsy, Lennox Gastaut Syndrome
RNS System LGS Feasibility Study
To generate preliminary safety and effectiveness data for brain-responsive neurostimulation of thalamocortical networks as an adjunctive therapy in reducing the frequency of generalized seizures in individuals 12 years of age or…
- Conditions
- Epilepsy, Lennox Gastaut Syndrome, Lennox-Gastaut Syndrome, Intractable, Seizures
- Trial name
- NCT05339126
- Testing
- RNS System
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- NeuroPace
Epilepsy
Cannabinoid Therapy for Pediatric Epilepsy
This is a Phase 1 trial to determine the tolerability and optimal dose of CBD rich cannabis extract as an adjunct treatment in children with severe drug resistant epilepsy due to Dravet Syndrome.
- Trial name
- NCT02983695
- Testing
- TIL-TC150
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- The Hospital for Sick Children
Sturge-Weber Syndrome
Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome
The purpose of this study is to determine the tolerability and optimal dose of cannabidiol (CBD) as an simultaneous treatment in children and young adults with Sturge-Weber syndrome (SWS) and drug resistant epilepsy.
- Trial name
- NCT02332655
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Anne Comi, MD
Epilepsy
P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.
In up to 1 out of 3 patients with epilepsy, seizures continue to occur despite the use of one or more antiepileptic medications.
- Trial name
- NCT00524134
- Testing
- Carvedilol-CR
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Epilepsy, Partial Seizure
RNS System RESPONSE Study
To demonstrate that the RNS System is safe and effective as an adjunctive therapy in individuals age 12 through 17 years with medically refractory partial onset epilepsy.
- Conditions
- Epilepsy, Partial Seizure, Neurostimulator; Complications, Drug Resistant Epilepsy
- Trial name
- RESPONSE (NCT04839601)
- Testing
- RNS System
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- NeuroPace
Epilepsy
Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy
Part A: To evaluate the safety and tolerability of multiple ascending doses of GWP42003-P compared with placebo with respect to: Incidence, type and severity of adverse events (AEs) Effect on vital signs, including weight Effect…
- Trial name
- NCT02286986
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Utah
Epilepsy, Epilepsy, Temporal Lobe
Surgery as a Treatment for Medically Intractable Epilepsy
Background: Drug resistant epilepsy is the term used to describe epilepsy that cannot be controlled by medication. Many people whose seizures do not respond to medication will respond to surgical treatment, relieving seizures…
- Conditions
- Epilepsy, Epilepsy, Temporal Lobe, Partial Epilepsy
- Trial name
- NCT01273129
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Epilepsy, Unspecified, Refractory (Medically)
The Use of Medicinal Cannabinoids as Adjunctive Treatment for Medically Refractory Epilepsy
Many families of children with medically refractory epilepsy are choosing to use medicinal cannabinoids (MCBD) as an adjunctive alternative treatment option. The safety, tolerability and efficacy of these products are not known.
- Trial name
- NCT02523183
- Testing
- Medical Cannabis
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Colorado, Denver
Epilepsy, Idiopathic Generalized Epilepsy
RNS System NAUTILUS Study
To demonstrate that the RNS System for thalamic stimulation is safe and effective as an adjunctive therapy for the reduction of primary generalized seizures in individuals 12 years of age or older who have drug-resistant…
- Conditions
- Epilepsy, Idiopathic Generalized Epilepsy, Generalized Tonic Clonic Seizure
- Trial name
- NAUTILUS (NCT05147571)
- Testing
- Responsive stimulation
- Where
- 23 sites in United States
- Volunteers
- 100 people
- Sponsor
- NeuroPace